Loading...
Ascendis Pharma A/S's top 1 named executive officers received combined total compensation of $16.3 million in fiscal year 2024.
The named executive officers disclosed in Ascendis Pharma A/S's 2024 proxy statement are:Fair Value Measurement () with total compensation of $16.3 million.
100% equity
Based on 20-F filed 2025-02-12 · FY2024
FY2024 total compensation breakdown
$16.3M total compensation
Fair Value Measurement earned $16.3M in FY2024 — here's how that breaks down.
$16.3M
100% of total
We need at least two years of pay and stock data to show the trend.
Pay changes vs. stock performance
Recent insider trades by officers and directors
53 trades
For analysts and deep research
Historical compensation data from latest proxy filing
| Year | Executive | Salary | Bonus & Incentive | Stock Awards | Option Awards | Other Adj. | Total |
|---|---|---|---|---|---|---|---|
| 2024 | Fair Value Measurement | $0.00M | $0.00M | $0.00M | $16.3M | $0.00M | $16.3M |
Salary = base cash pay. Bonus & Incentive combines annual bonus and non-equity plans. Equity amounts are grant-date fair values. Other Adj. captures pension changes, perquisites, and any reconciliation items so the total matches the reported figure.
Get one email when new executive compensation data is filed and processed.